Top

Published in:

Open Access 01-06-2019 | Review

MRI combined with PET-CT of different tracers to improve the accuracy of glioma diagnosis: a systematic review and meta-analysis

Authors: Yihan Yang, Mike Z. He, Tao Li, Xuejun Yang

Published in: Neurosurgical Review | Issue 2/2019

Abstract

Based on studies focusing on positron emission tomography (PET)-computed tomography (CT) combined with magnetic resonance imaging (MRI) in the diagnosis of glioma, we conducted a systematic review and meta-analysis evaluating the pros and cons and the accuracy of different examinations. PubMed and Cochrane Library were searched. The search was conducted until April 2017. Two reviewers independently conducted the literature search according to the criteria set initially. Based on the exclusion criteria, 15 articles are included in this study. Of all studies that used MRI examination, there are five involving 18F-fluorodeoxyglucose-PET, five involving 11C-methionine-PET, five involving 18F-fluoro-ethyl-tyrosine-PET, and three involving 18F-fluorothymidine-PET. Due to the limitations such as lack of data, small sample size, and unrepresentative studies, we use a non-quantitative methodology. MRI examination can provide the anatomy information of glioma more clearly. PET-CT examinations based on tumor metabolism using different tracers have more advantages in determining the degree of glioma malignancy and boundaries. However, information provided by PET-CT of different tracers is not the same. With respect to the novel hybrid MRI/PET examination equipment proposed in recent years, the combination of MRI and PET-CT can definitively improve the diagnostic accuracy of glioma.

Ahmed R, Oborski MJ, Hwang M, Lieberman FS, Mountz JM (2014) Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods. Cancer Manag Res 6:149–170. https://doi.org/10.2147/CMAR.S54726 CrossRefPubMedPubMedCentral

Arbizu J, Tejada S, Marti-Climent JM, Diez-Valle R, Prieto E, Quincoces G, Vigil C, Idoate MA, Zubieta JL, Peñuelas I, Richter JA (2012) Quantitative volumetric analysis of gliomas with sequential MRI and 11C-methionine PET assessment: patterns of integration in therapy planning. Eur J Nucl Med Mol Imaging 39:771–781. https://doi.org/10.1007/s00259-011-2049-9 CrossRefPubMed

Bach-Gansmo T, Nanni C, Nieh PT, Zanoni L, Bogsrud TV, Sletten H, Korsan K, Kieboom J, Tade F, Odewole O, Chau A, Ward P, Goodman MM, Fanti S, Schuster DM, Willoch F (2016) Multi-site experience of the safety, detection rate and diagnostic performance of fluciclovine (18F) PET/CT imaging in the staging of biochemically recurrent prostate cancer. J Urol. https://doi.org/10.1016/j.juro.2016.09.117

Bailey DL, Barthel H, Beyer T, Boellaard R, Gückel B, Hellwig D, Herzog H, Pichler BJ, Quick HH, Sabri O, Scheffler K, Schlemmer HP, Schwenzer NF, Wehrl HF (2013) Summary report of the first international workshop on PET/MR imaging, March 19-23, 2012, Tübingen, Germany. Mol Imaging Biol 15:361–371. https://doi.org/10.1007/s11307-013-0623-1 CrossRefPubMedPubMedCentral

Barwick T, Bencherif B, Mountz JM, Avril N (2009) Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation. Nucl Med Commun 30:908–917. https://doi.org/10.1097/MNM.0b013e32832ee93b CrossRefPubMed

Belliveau J-G, Bauman G, Macdonald DR (2016) Detecting tumor progression in glioma: current standards and new techniques. Expert Rev Anticancer Ther 1–12. https://doi.org/10.1080/14737140.2016.1240621

Belohlavek O, Fencl P, Majovsky M, Jaruskova M, Benes V (2014) FLT-PET in previously untreated patients with low-grade glioma can predict their overall survival. Nucl Med Rev 17:7–12. https://doi.org/10.5603/NMR.2014.0003 CrossRef

Bergström M, Collins VP, Ehrin E, Ericson K, Eriksson L, Greitz T, Halldin C, von Holst H, Långström B, Lilja A (1983) Discrepancies in brain tumor extent as shown by computed tomography and positron emission tomography using [68Ga]EDTA, [11C]glucose, and [11C]methionine. J Comput Assist Tomogr 7:1062–1066CrossRefPubMed

Bustany P, Chatel M, Derlon JM, Darcel F, Sgouropoulos P, Soussaline F, Syrota A (1986) Brain tumor protein synthesis and histological grades: a study by positron emission tomography (PET) with C11-L-methionine. J Neuro-Oncol 3:397–404CrossRef

10.

Collet S, Valable S, Constans JM, Lechapt-Zalcman E, Roussel S, Delcroix N, Abbas A, Ibazizene M, Bernaudin M, Barré L, Derlon JM, Guillamo JS (2015) [¹⁸F]-fluoro-l-thymidine PET and advanced MRI for preoperative grading of gliomas. NeuroImage Clin 8:448–454. https://doi.org/10.1016/j.nicl.2015.05.012 CrossRefPubMedPubMedCentral

11.

De Witte O, Levivier M, Violon P, Salmon I, Damhaut P, Wikler D Jr, Hildebrand J, Brotchi J, Goldman S (1996) Prognostic value of positron emission tomography with [18F]fluoro-2-deoxy-D-glucose in the low-grade glioma. Neurosurgery 39:470–476PubMed

12.

De Witte O, Goldberg I, Wikler D, Rorive S, Damhaut P, Monclus M, Salmon I, Brotchi J, Goldman S (2001) Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg 95:746–750. https://doi.org/10.3171/jns.2001.95.5.0746 CrossRefPubMed

13.

Dean BL, Drayer BP, Bird CR, Flom RA, Hodak JA, Coons SW, Carey RG (1990) Gliomas: classification with MR imaging. Radiology 174:411–415. https://doi.org/10.1148/radiology.174.2.2153310 CrossRefPubMed

14.

Derlon JM, Bourdet C, Bustany P, Chatel M, Theron J, Darcel F, Syrota A (1989) [11C]L-methionine uptake in gliomas. Neurosurgery 25:720–728CrossRefPubMed

15.

Devaux BC, O’Fallon JR, Kelly PJ (1993) Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg 78:767–775. https://doi.org/10.3171/jns.1993.78.5.0767 CrossRefPubMed

16.

Dooms GC, Hecht S, Brant-Zawadzki M, Berthiaume Y, Norman D, Newton TH (1986) Brain radiation lesions: MR imaging. Radiology 158:149–155. https://doi.org/10.1148/radiology.158.1.3940373 CrossRefPubMed

17.

Ewelt C, Floeth FW, Felsberg J, Steiger HJ, Sabel M, Langen KJ, Stoffels G, Stummer W (2011) Finding the anaplastic focus in diffuse gliomas: the value of Gd-DTPA enhanced MRI, FET-PET, and intraoperative, ALA-derived tissue fluorescence. Clin Neurol Neurosurg 113:541–547. https://doi.org/10.1016/j.clineuro.2011.03.008 CrossRefPubMed

18.

Floeth FW, Pauleit D, Sabel M, Reifenberger G, Stoffels G, Stummer W, Rommel F, Hamacher K, Langen K-J (2006) 18F-FET PET differentiation of ring-enhancing brain lesions. J Nucl Med 47:776–782PubMed

19.

Floeth FW, Pauleit D, Sabel M, Stoffels G, Reifenberger G, Riemenschneider MJ, Jansen P, Coenen HH, Steiger H-J, Langen K-J (2007) Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma. J Nucl Med 48:519–527. https://doi.org/10.2967/jnumed.106.037895 CrossRefPubMed

20.

Floeth FW, Sabel M, Stoffels G, Pauleit D, Hamacher K, Steiger HJ, Langen KJ (2008) Prognostic value of (18)F-fluoroethyl-L-tyrosine PET and MRI in small nonspecific incidental brain lesions. J Nucl Med 49:730–737. https://doi.org/10.2967/jnumed.107.050005 CrossRefPubMed

21.

Fouke SJ, Benzinger T, Gibson D, Ryken TC, Kalkanis SN, Olson JJ (2015) The role of imaging in the management of adults with diffuse low grade glioma: a systematic review and evidence-based clinical practice guideline. J Neuro-Oncol 125:457–479. https://doi.org/10.1007/s11060-015-1908-9 CrossRef

22.

Grierson JR, Shields AF (2000) Radiosynthesis of 3Ј-deoxy-3Ј-[18F]fluorothymidine: [18F] FLT for imaging of cellular proliferation in vivo. Science (80- ) 27:143–156

23.

Grosu AL, Weber WA, Riedel E, Jeremic B, Nieder C, Franz M, Gumprecht H, Jaeger R, Schwaiger M, Molls M (2005) L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys 63:64–74. https://doi.org/10.1016/j.ijrobp.2005.01.045 CrossRefPubMed

24.

Herholz K, Bauer B, Hölzer T, Thiel A, Wienhard K, Heiss W-D, Weber-Luxenburge G, Mendoza G, Ernestus R-I, Voges J, Schroder R (1998) C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 50:1316–1322. https://doi.org/10.1212/WNL.50.5.1316 CrossRefPubMed

25.

Huk W, Gademann G (1984) Magnetic resonance imaging (MRI): method and early clinical experiences in diseases of the central nervous system. Neurosurg Rev 7:259–280CrossRefPubMed

26.

Hutterer M, Nowosielski M, Putzer D, Jansen NL, Seiz M, Schocke M, McCoy M, Göbel G, La Fougère C, Virgolini IJ, Trinka E, Jacobs AH, Stockhammer G (2013) [18F]-fluoro-ethyl-l-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. Neuro-Oncology 15:341–351. https://doi.org/10.1093/neuonc/nos300 CrossRefPubMedPubMedCentral

27.

Imani F, Boada FE, Lieberman FS, Davis DK, Deeb EL, Mountz JM (2012) Comparison of proton magnetic resonance spectroscopy with fluorine-18 2-fluoro-deoxyglucose positron emission tomography for assessment of brain tumor progression. J Neuroimaging 22:184–190. https://doi.org/10.1111/j.1552-6569.2010.00561.x CrossRefPubMed

28.

Jacobs AH, Thomas A, Kracht LW, Li H, Dittmar C, Garlip G, Galldiks N, Klein JC, Sobesky J, Hilker R, Vollmar S, Herholz K, Wienhard K, Heiss W-D (2005) 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med 46:1948–1958PubMed

29.

Jansen NL, Graute V, Armbruster L, Suchorska B, Lutz J, Eigenbrod S, Cumming P, Bartenstein P, Tonn JC, Kreth FW, La Fougère C (2012) MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET? Eur J Nucl Med Mol Imaging 39:1021–1029. https://doi.org/10.1007/s00259-012-2109-9 CrossRefPubMed

30.

Jansen NL, Suchorska B, Wenter V, Schmid-Tannwald C, Todica A, Eigenbrod S, Niyazi M, Tonn JC, Bartenstein P, Kreth FW, la Fougere C (2015) Prognostic significance of dynamic 18F-FET PET in newly diagnosed astrocytic high-grade glioma. J Nucl Med 56:9–15. https://doi.org/10.2967/jnumed.114.144675 CrossRefPubMed

31.

Jensen JH, Helpern JA (2010) MRI quantification of non-Gaussian water diffusion by kurtosis analysis. NMR Biomed 23:698–710. https://doi.org/10.1002/nbm.1518 CrossRefPubMedPubMedCentral

32.

Jung T-Y, Min J-J, Bom H-S, Jung S, Kim I-Y, Lim S-H, Kim D-Y, Kwon SY (2016) Prognostic value of post-treatment metabolic tumor volume from 11C-methionine PET/CT in recurrent malignant glioma. Neurosurg Rev. https://doi.org/10.1007/s10143-016-0748-1

33.

Kaschten B, Stevenaert A, Sadzot B, Deprez M, Degueldre C, Del Fiore G, Luxen A, Reznik M (1998) Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 39:778–785PubMed

34.

Khan M, Sharma A, Pitz M, Loewen S, Quon H, Poulin A, Essig M (2016) High-grade glioma management and response assessment—recent advances and current challenges. Curr Oncol 23:383–391. https://doi.org/10.3747/co.23.3082 CrossRef

35.

Kinoshita M, Hashimoto N, Goto T, Yanagisawa T, Okita Y, Kagawa N, Kishima H, Tanaka H, Fujita N, Shimosegawa E, Hatazawa J, Yoshimine T (2009) Use of fractional anisotropy for determination of the cut-off value in 11C-methionine positron emission tomography for glioma. NeuroImage 45:312–318. https://doi.org/10.1016/j.neuroimage.2008.11.034 CrossRefPubMed

36.

Kobayashi K, Hirata K, Yamaguchi S, Manabe O, Terasaka S, Kobayashi H, Shiga T, Hattori N, Tanaka S, Kuge Y, Tamaki N (2015) Prognostic value of volume-based measurements on 11C-methionine PET in glioma patients. Eur J Nucl Med Mol Imaging 42:1071–1080. https://doi.org/10.1007/s00259-015-3046-1 CrossRefPubMed

37.

Kracht LW, Miletic H, Busch S, Jacobs AH, Voges J, Hoevels M, Klein JC, Herholz K, Heiss WD (2004) Delineation of brain tumor extent with [11C] l-methionine positron emission tomography. Clin Cancer Res 10:7163CrossRefPubMed

38.

Kumthekar P, Raizer J, Singh S (2015) Low-grade glioma. Cancer Treat Res 163:75–87CrossRefPubMed

39.

Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190–198. https://doi.org/10.3171/jns.2001.95.2.0190 CrossRefPubMed

40.

Langen KJ, Hamacher K, Weckesser M, Floeth F, Stoffels G, Bauer D, Coenen HH, Pauleit D (2006) O-(2-[18F]fluoroethyl)-l-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol 33:287–294. https://doi.org/10.1016/j.nucmedbio.2006.01.002 CrossRefPubMed

41.

Löbel U, Ellison DW, Shulkin BL, Patay Z (2011) Infiltrative cerebellar ganglioglioma: conventional and advanced MRI, proton MR spectroscopic, and FDG PET findings in an 18- month-old child. Clin Radiol 66:194–201. https://doi.org/10.1016/j.crad.2010.10.005 CrossRefPubMed

42.

Lupo JM, Nelson SJ (2014) Advanced magnetic resonance imaging methods for planning and monitoring radiation therapy in patients with high-grade glioma. Semin Radiat Oncol 24:248–258. https://doi.org/10.1016/j.semradonc.2014.06.008 CrossRefPubMedPubMedCentral

43.

Miwa K, Shinoda J, Yano H, Okumura A, Iwama T, Nakashima T, Sakai N (2004) Discrepancy between lesion distributions on methionine PET and MR images in patients with glioblastoma multiforme: insight from a PET and MR fusion image study. J Neurol Neurosurg Psychiatry 75:1457–1462. https://doi.org/10.1136/jnnp.2003.028480 CrossRefPubMedPubMedCentral

44.

Mosskin M, Ericson K, Hindmarsh T, Von Holst H, Collins VP, Bergstrom M, Eriksson L, Johnstrom P (1989) Positron emission tomography compared with magnetic resonance imaging and computed tomography in supratentorial gliomas using multiple stereotactic biopsies as reference. Acta Radiol 30:225–232. https://doi.org/10.1177/028418518903000301 CrossRefPubMed

45.

Muzi M, Freeman SD, Burrows RC, Wiseman RW, Link JM, Krohn KA, Graham MM, Spence AM (2001) Kinetic characterization of hexokinase isoenzymes from glioma cells: implications for FDG imaging of human brain tumors. Nucl Med Biol 28:107–116. https://doi.org/10.1016/S0969-8051(00)00201-8 CrossRefPubMed

46.

Nihashi T, Dahabreh IJ, Terasawa T (2013) PET in the clinical management of glioma: evidence map. Am J Roentgenol 200:654–660. https://doi.org/10.2214/AJR.12.9168 CrossRef

47.

Nowosielski M, DiFranco MD, Putzer D, Seiz M, Recheis W, Jacobs AH, Stockhammer G, Hutterer M (2014) An intra-individual comparison of MRI, [18F]-FET and [ 18F]-FLT PET in patients with high-grade gliomas. PLoS One. https://doi.org/10.1371/journal.pone.0095830

48.

Nuutinen J, Sonninen P, Lehikoinen P, Sutinen E, Valavaara R, Eronen E, Norrgård S, Kulmala J, Teräs M, Minn H (2000) Radiotherapy treatment planning and long-term follow-up with [(11)C]methionine PET in patients with low-grade astrocytoma. Int J Radiat Oncol Biol Phys 48:43–52

49.

Ogawa T, Shishido F, Kanno I, Inugami A, Fujita H, Murakami M, Shimosegawa E, Ito H, Hatazawa J, Okudera T (1993) Cerebral glioma: evaluation with methionine PET. Radiology 186:45–53CrossRefPubMed

50.

Okamoto Y, Di Patre PL, Burkhard C, Horstmann S, Jourde B, Fahey M, Schüler D, Probst-Hensch NM, Yasargil MG, Yonekawa Y, Lütolf UM, Kleihues P, Ohgaki H (2004) Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol 108:49–56. https://doi.org/10.1007/s00401-004-0861-z CrossRefPubMed

51.

Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, Stroup NE, Kruchko C, Barnholtz-Sloan JS (2013) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro-Oncology 15

52.

Paldino MJ, Wong TZ, Reardon DA, Friedman HS, Barboriak DP (2011) Prognostic significance of parameters derived from co-registered 18F-fluorodeoxyglucose PET and contrast-enhanced MRI in patients with high-grade glioma. Br J Radiol 84:327. https://doi.org/10.1259/bjr/48528504 CrossRefPubMedPubMedCentral

53.

Perry A, Wesseling P (2016) Histologic classification of gliomas, 1st ed. Handb Clin Neurol doi:https://doi.org/10.1016/B978-0-12-802997-8.00005-0

54.

Pichler R, Dunzinger A, Wurm G, Pichler J, Weis S, Nubaumer K, Topakian R, Aigner RM (2010) Is there a place for FET PET in the initial evaluation of brain lesions with unknown significance? Eur J Nucl Med Mol Imaging 37:1521–1528. https://doi.org/10.1007/s00259-010-1457-6 CrossRefPubMed

55.

Piñeros M, Sierra MS, Izarzugaza MI, Forman D (2016) Descriptive epidemiology of brain and central nervous system cancers in Central and South America. Cancer Epidemiol 44:S141–S149. https://doi.org/10.1016/j.canep.2016.04.007 CrossRefPubMed

56.

Plotkin M, Blechschmidt C, Auf G, Nyuyki F, Geworski L, Denecke T, Brenner W, Stockhammer F (2010) Comparison of F-18 FET-PET with F-18 FDG-PET for biopsy planning of non-contrast-enhancing gliomas. Eur Radiol 20:2496–2502. https://doi.org/10.1007/s00330-010-1819-2 CrossRefPubMed

57.

Pöpperl G, Götz C, Rachinger W, Gildehaus FJ, Tonn JC, Tatsch K (2004) Value of O-(2-[18F]fluoroethyl)-L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging 31:1464–1470. https://doi.org/10.1007/s00259-004-1590-1 CrossRefPubMed

58.

Pöpperl G, Kreth FW, Mehrkens JH, Herms J, Seelos K, Koch W, Gildehaus FJ, Kretzschmar HA, Tonn JC, Tatsch K (2007) FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging 34:1933–1942. https://doi.org/10.1007/s00259-007-0534-y CrossRefPubMed

59.

Price SJ (2007) The role of advanced MR imaging in understanding brain tumour pathology. Br J Neurosurg 21:562–575. https://doi.org/10.1080/02688690701700935 CrossRefPubMed

60.

Puttick S, Bell C, Dowson N, Rose S, Fay M (2015) PET, MRI, and simultaneous PET/MRI in the development of diagnostic and therapeutic strategies for glioma. Drug Discov Today 20:306–317. https://doi.org/10.1016/j.drudis.2014.10.016 CrossRefPubMed

61.

Rachinger W, Goetz C, Pöpperl G, Gildehaus FJ, Kreth FW, Holtmannspötter M, Herms J, Koch W, Tatsch K, Tonn JC (2005) Positron emission tomography with O-(2-[18F]flouroethyl)-L- tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery 57:505–511. https://doi.org/10.1227/01.NEU.0000171642.49553.B0 CrossRefPubMed

62.

Rahm V, Boxheimer L, Bruehlmeier M, Berberat J, Nitzsche EU, Remonda L, Roelcke U (2014) Focal changes in diffusivity on apparent diffusion coefficient MR imaging and amino acid uptake on PET do not colocalize in nonenhancing low-grade gliomas. J Nucl Med 55:546–550. https://doi.org/10.2967/jnumed.113.130732 CrossRefPubMed

63.

Ricci PE, Dungan DH (2001) Imaging of low- and intermediate-grade gliomas. Semin Radiat Oncol 11:103–112. https://doi.org/10.1053/srao.2001.21420 CrossRefPubMed

64.

Roessler K, Gatterbauer B, Becherer A, Paul M, Kletter K, Prayer D, Hoeftberger R, Hainfellner J, Asenbaum S, Knosp E (2007) Surgical target selection in cerebral glioma surgery: linking methionine (MET) PET image fusion and neuronavigation. Minim Invasive Neurosurg 50:273–280. https://doi.org/10.1055/s-2007-991143 CrossRefPubMed

65.

Sanai N, Berger MS (2008) Glioma extent of resection and its impact on patient outcome. Neurosurgery 62:753–764CrossRefPubMed

66.

Santra A, Kumar R, Sharma P, Bal C, Kumar A, Julka PK, Malhotra A (2012) F-18 FDG PET-CT in patients with recurrent glioma: comparison with contrast enhanced MRI. Eur J Radiol 81:508–513. https://doi.org/10.1016/j.ejrad.2011.01.080 CrossRefPubMed

67.

Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Geist C, Dahlbom M, Silverman DH, Satyamurthy N, Phelps ME, Chen W (2012) 3′-Deoxy-3′-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med 53:29–36. https://doi.org/10.2967/jnumed.111.092387 CrossRefPubMed

68.

Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, Obradovich JE, Muzik O, Mangner TJ (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4:1334–1336. https://doi.org/10.1038/3337 CrossRefPubMed

69.

Shinomiya A, Kawai N, Okada M, Miyake K, Nakamura T, Kushida Y, Haba R, Kudomi N, Yamamoto Y, Tokuda M, Tamiya T (2013) Evaluation of 3′-deoxy-3′-[18F]-fluorothymidine (18F-FLT) kinetics correlated with thymidine kinase-1 expression and cell proliferation in newly diagnosed gliomas. Eur J Nucl Med Mol Imaging 40:175–185. https://doi.org/10.1007/s00259-012-2275-9 CrossRefPubMed

70.

Singhal T, Narayanan TK, Jain V, Mukherjee J, Mantil J (2008) 11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas. Mol Imaging Biol 10:1–18. https://doi.org/10.1007/s11307-007-0115-2 CrossRefPubMed

71.

Singhal T, Narayanan TK, Jacobs MP, Bal C, Mantil JC (2012) 11C-Methionine PET for grading and prognostication in gliomas: a comparison study with 18F-FDG PET and contrast enhancement on MRI. J Nucl Med 53:1709–1715. https://doi.org/10.2967/jnumed.111.102533 CrossRefPubMed

72.

Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, Tihan T, Vandenberg S, McDermott MW, Berger MS (2008) Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 26:1338–1345CrossRefPubMed

73.

Smits A, Baumert BG (2011) The clinical value of PET with amino acid tracers for gliomas WHO grade II. Int J Mol Imaging 2011:372509. https://doi.org/10.1155/2011/372509 CrossRefPubMedPubMedCentral

74.

Stockhammer F, Plotkin M, Amthauer H, Landeghem FKH, Woiciechowsky C (2008) Correlation of F-18-fluoro-ethyl-tyrosin uptake with vascular and cell density in non-contrast-enhancing gliomas. J Neuro-Oncol 88:205–210. https://doi.org/10.1007/s11060-008-9551-3 CrossRef

75.

Stupp R, Tonn JC, Brada M, Pentheroudakis G (2010) High-grade malignant glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:190–193. https://doi.org/10.1093/annonc/mdq187 CrossRef

76.

Tovi M, Lilja A, Bergstrom M, Ericsson A, Bergstrom K, Hartman M (1990) Delineation of gliomas with magnetic resonance imaging using Gd-DTPA in comparison with computed tomography and positron emission tomography. Acta Radiol 31:417–429. https://doi.org/10.1080/02841859009173067

77.

Upadhyay N, Waldman AD (2011) Conventional MRI evaluation of gliomas. Br J Radiol 84:107–111. https://doi.org/10.1259/bjr/65711810 CrossRef

78.

van Dellen JR, Danziger A (1978) Failure of computerized tomography to differentiate between radiation necrosis and cerebral tumour. S Afr Med J 53:171–172PubMed

79.

Vézina L-G (2008) Imaging of CNS tumors in children: advances and limitations. J Child Neurol 23:1128–1135. https://doi.org/10.1177/0883073808320753.Imaging CrossRefPubMedPubMedCentral

80.

Wang X, Chen J, Zhou Q, Liu Y, Mao Q, You C, Chen N, Xiong L, Duan J, Liu L (2016) Statistical report of central nervous system tumors histologically diagnosed in the Sichuan Province of China from 2008 to 2013: a West China Glioma Center report. Ann Surg Oncol. https://doi.org/10.1245/s10434-016-5410-1

81.

Weckesser M, Langen KJ, Rickert CH, Kloska S, Straeter R, Hamacher K, Kurlemann G, Wassmann H, Coenen HH, Schober O (2005) O-(2-[18F]fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours. Eur J Nucl Med Mol Imaging 32:422–429. https://doi.org/10.1007/s00259-004-1705-8 CrossRefPubMed

82.

Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, DeGroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, Van Den Bent MJ, Chang SM (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972. https://doi.org/10.1200/JCO.2009.26.3541 CrossRefPubMed

83.

Wester H, Herz M, Weber W, Heiss P, Senekowitsch-Schmidtke R, Schwaiger M, Stöcklin G (1999) Synthesis and radiopharmacology of O-(2-fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med 40:205–212PubMed

84.

Yamamoto Y, Wong TZ, Turkington TG, Hawk TC, Reardon DA, Coleman RE (2006) 3′-Deoxy-3′-[F-18]fluorothymidine positron emission tomography in patients with recurrent glioblastoma multiforme: comparison with Gd-DTPA enhanced magnetic resonance imaging. Mol Imaging Biol MIB Off Publ Acad Mol Imaging 8:340–347. https://doi.org/10.1007/s11307-006-0063-2 CrossRef

85.

Yoo MY, Paeng JC, Cheon GJ, Lee DS, Chung JK, Kim EE (2010) Kang KW (2015) prognostic value of metabolic tumor volume on 11C-methionine PET in predicting progression-free survival in high-grade glioma. Nucl Med Mol Imaging 49:291–297. https://doi.org/10.1007/s13139-015-0362-0 CrossRef

86.

Zhao F, Li M, Wang Z, Fu Z, Cui Y, Chen Z, Yu J (2015) ¹⁸F-fluorothymidine PET-CT for resected malignant gliomas before radiotherapy: tumor extent according to proliferative activity compared with MRI. PLoS One 10:1–12. https://doi.org/10.1371/journal.pone.0118769 CrossRef

87.

Zonari P, Baraldi P, Crisi G (2007) Multimodal MRI in the characterization of glial neoplasms: the combined role of single-voxel MR spectroscopy, diffusion imaging and echo-planar perfusion imaging. Neuroradiology. https://doi.org/10.1007/s00234-007-0253-x

Title: MRI combined with PET-CT of different tracers to improve the accuracy of glioma diagnosis: a systematic review and meta-analysis
Authors: Yihan Yang
Mike Z. He
Tao Li
Xuejun Yang
Publication date: 01-06-2019
Publisher: Springer Berlin Heidelberg
Published in: Neurosurgical Review / Issue 2/2019
Print ISSN: 0344-5607
Electronic ISSN: 1437-2320
DOI: https://doi.org/10.1007/s10143-017-0906-0

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

MRI combined with PET-CT of different tracers to improve the accuracy of glioma diagnosis: a systematic review and meta-analysis

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2019

Rate and risk factors for a hyperactivity delirium in patients with aneurysmal subarachnoid haemorrhage

Characteristic features and proposed classification in 69 cases of intracranial microcystic meningiomas

Safety and accuracy of spinal instrumentation surgery in a hybrid operating room with an intraoperative cone-beam computed tomography

Pain medication at ictus of subarachnoid hemorrhage—the influence of one-time acetylsalicylic acid usage on bleeding pattern, treatment course, and outcome: a matched pair analysis

Efficacy of superficial temporal artery-middle cerebral artery double bypass in patients with hemorrhagic moyamoya disease: surgical effects for operated hemispheric sides

Correction to: Efficacy of superficial temporal artery-middle cerebral artery double bypass in patients with hemorrhagic moyamoya disease: surgical effects for operated hemispheric sides